Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer — retrospective analysis
Abstract
Background: Treatment with sole ultra-low dose rate brachytherapy (uLDR-BT) for unfavorable intermediate risk factor (IUR) group prostate cancer patients is not recommended by guidelines due to the lack of strong evidence of its effectiveness. However, there were numerous patients treated with good results with this method in older trials. Purpose of this work was to retrospectively asses effectiveness of uLDR-BT in IUR group treated in our department.
Materials and methods: We performed retrospective analysis of 39 IUR prostate cancer patients treated in our department with uLDR-BT between 2015–2019. All Patients had confirmed prostate cancer in biopsy and had local staging assessed with digital rectal examination and either transrectal ultrasound (TRUS) or magnetic resonance imaging (MRI) before treatment. Treatment was performed using 125I seeds, and the dose prescribed to the clinical target volume was 145 Gy. After treatment, all patients were followed in our outpatient ambulatory one month after the procedure and every 3–6 months later on. Toxicity was assessed using the International Prostate Symptom Score (IPSS) and Radiation Therapy Oncology Group (RTOG) scales.
Results: The median follow-up was 56,3 months [interquartile range (IQR): 36.9–73.4]. The mean nadir prostate-specific antigen (PSA) was 0.20 ng/mL (range 0.001–1.7). The actuarial 5-year biochemical failure-free survival (BFFS) was 87.02%. There was no statistically significant difference in BFFS between groups with antigen deprivation therapy (ADT) and without (p = 0.439). Analysis also showed no impact on BFFS of each intermediate group risk factors: initial PSA (iPSA) (p = 0.595). Gleason (p = 0.671) and Tumor stage (p = 0.694). There were no statistically significant differences in BFFS depending on number of those factors (p = 0.330). Conclusion The uLDR-BT may be an effective option for selected IUR prostate cancer patients.
Keywords: prostate cancerbrachytherapylow-dose brachytherapy
References
- Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021; 79(2): 243–262.
- Yavaş G. Dose Rate Definition in Brachytherapy. Turk J Oncol. 2019.
- National Comprehensive Cancer Network. Prostate Cancer (Version 2.2023). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (July 23, 2023).
- Pickles T, Morris WJ, Keyes M. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy. Brachytherapy. 2017; 16(6): 1101–1105.
- Frank SJ, Pugh TJ, Blanchard P, et al. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018; 100(2): 374–382.
- Tsumura H, Tanaka N, Oguchi T, et al. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Radiat Oncol. 2022; 17(1): 71.
- Tom MC, Reddy CA, Smile TD, et al. Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy. 2020; 19(1): 43–50.
- Robin S, Chabaud S, Serre AA, et al. Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival. J Contemp Brachytherapy. 2021; 13(4): 373–386.
- Andruska N, Fischer-Valuck BW, Carmona R, et al. Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone. J Natl Compr Canc Netw. 2022; 20(4): 343–350.e4.
- Henry A, Pieters BR, André Siebert F, et al. UROGEC group of GEC ESTRO with endorsement by the European Association of Urology. GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiother Oncol. 2022; 167: 244–251.
- Kittel JA, Reddy CA, Smith KL, et al. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2015; 92(4): 884–893.
- Henry AM, Al-Qaisieh B, Gould K, et al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys. 2010; 76(1): 50–56.
- Ciezki JP, Weller M, Reddy CA, et al. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017; 97(5): 962–975.
- Lardas M, Liew M, van den Bergh RC, et al. Quality of life outcomes after primary treatment for clinically localized prostate cancer: a systematic review. Eur Urol. 2017; 72(6): 886–887.
- Roach M, Ceron Lizarraga TL, Lazar AA. Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence? Int J Radiat Oncol Biol Phys. 2015; 93(5): 1064–1070.
- Beauval JB, Ploussard G, Cabarrou B, et al. Committee of Cancerology of the Association of French Urology. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. World J Urol. 2017; 35(8): 1191–1197.
- Dubray BM, Beckendorf V, Guerif S, et al. Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741). J Clin Oncol. 2011; 29(15_suppl): 4521–4521.
- Michalski JM, Winter KA, Prestidge BR, et al. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial. J Clin Oncol. 2023; 41(24): 4035–4044.
- Willen BD, Salari K, Zureick AH, et al. High-dose-rate brachytherapy as monotherapy versus as boost in unfavorable intermediate-risk localized prostate cancer: A matched-pair analysis. Brachytherapy. 2023; 22(5): 571–579.
- Crook JM, Tang C, Thames H, et al. A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol. 2020; 149: 64–69.